MTOR and liver cancer: In line with these findings, treatment with rapamycin, the prototypic mTOR inhibitor, significantly reduces the frequency of CD133+/EpCAM+ cells in Hep3B and Huh7, which are widely considered liver cancer stem cell populations [52].